The preliminary data with lung cancer with zybrestat was positive!
The stock will not make any sustainable and meaningful gain until they sign a partnership. If they can't sign a decent partner deal with good phase 2 Ovarian, ATC and Lung data, we are S^^& out luck and it's over, although I don't believe that will be the case
Partnership isn't the only way out, money via private, stock dilution or other means could be raised to proceed with further trials. If they do it on their own and end results are able to go fda route then Other companies will be banging at the door. IF they do it alone = more profit for share holders in the long run.
I agree that upcoming data is good enough deal will be struck right away, but DO NOT agree only way out and we are screwed. UP FROM HERE.